TrialEffect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Trial details
- Registry ID
- NCT05721729
- Phase
- Phase 2
Drug research
Mizagliflozin
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose ExcursionsNCT05721729 | VOGX | Phase 2 | Completed | 2024-05-01Actual |
| Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia SubjectsNCT05541939 | VOGX | Phase 2 | Completed | 2023-02-17Actual |
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
Trial details
- Registry ID
- NCT05541939
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |